Lack of any relationship between chemotherapy toxicity in non-small cell Lung cancer cases and polymorphisms in XRCC1 Codon 399 or XPD Codon 751

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 3, 2011, Pages 739-742

  Li, Yan ^a,b   Huang, Xin En ^a,b   Jin, Guang Fu ^b   Shen, Hong Bin ^b   Xu, Lin ^a,b  

^a JIANGSU CANCER HOSPITAL   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Non small cell lung cancer; Toxicity; XPD; XRCC1

Indexed keywords

EID: 79958824467     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benhamou S, Sarasin A. (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9.
2. Booton R, Ward T, Heighway J, et al. (2006). Xeroderma Pigmentosum Group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer, 106,2421-7.
3. Chang-Claude J, Popanda O, Tan XL, et al. (2005). Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res, 11, 4802-9.
4. Chen S, Tang D, Xue K, et al. (2002). DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis, 23, 1321-5.
5. Cheng XD, Lu WG, Ye F, Wan XY, Xie X. (2009). The association of XRCC1 gene single nucleotide polymorphisms with response to neoadjuvant chemotherapy in locally advanced cervical carcinoma. J Exp Clin Cancer Res, 28, 91.
6. DCTD, NCI, NIH, DHHS. (2006). Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0. Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf#search="CTCAE".
7. Font A, Salazar R, Maurel J, et al. (2008). Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms. Cancer Chemother Pharmacol, 62, 1075-83.
8. Giachino DF, Ghio P, Regazzoni S, et al. (2007). Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res, 13, 2876-81.
9. Kuptsova N, Kopecky KJ, Godwin J, et al. (2007). Polymorphisms in DNA repair genes and therapeutic outcomes of AML patients from SWOG clinical trials. Blood, 109, 3936-44.
10. Lindahl T, Wood RD. (1999). Quality control by DNA repair. Science, 286, 1897-905.
11. Muss HB, Berry DA, Cirrincione C, et al. (2007) .Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol, 25, 3699-704.
12. Norppa H. (2004). Cytogenetic biomarkers and genetic polymorphisms. Toxicol Letters, 149, 309-34.
13. Schiller JH, Harrington D, Belani CP, et al. (2002).Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
14. Sloan JA, Goldberg RM, Sargent DJ, et al. (2002). Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol, 20, 1491-8.
15. Stata Corporation. Stata 8.0 software. College Station, TX: Stata Corporation, 2003.
16. Sun X, Li F, Sun N, et al. (2009). Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer, 65, 230-6.
17. Tibaldi C, Giovannetti E, Vasile E, et al. (2008). Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res, 14, 1797-803.
18. Wang Z, Xu B, Lin D, et al. (2008).XRCC1 polymorphisms and severe toxicity in lung cancer patients treated with cisplatin-based chemotherapy in Chinese population. Lung Cancer, 62, 99-104.
19. Xing D, Qi J, Miao X, et al. (2002). Polymorphisms of DNA repair genes XRCC1 and XPD and their associations with risk of esophageal squamous cell carcinoma in a Chinese population. Int J Cancer, 100, 600-5.
20. Yao CY, Huang XE, Li C, et al. (2009). Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pacific J Cancer Prev, 10, 859-64.
21. Zhou JN, Huang XE, Ye Z, et al. (2009). Weekly paclitaxel/ docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pacific J Cancer Prev, 10, 1147-50.